New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:35 EDTPETXAratana Therapeutics initiates pivotal study for AT-001
Aratana Therapeutics announced the initiation of the pivotal field effectiveness study for AT-001, the company's innovative drug for treating pain in dogs with osteoarthritis. The randomized, blinded, multicenter pivotal study will enroll approximately 300 client-owned dogs with osteoarthritis, and will be conducted under a study protocol for which Aratana received concurrence from the FDA's Center for Veterinary Medicine. The primary endpoint will be a reduction in osteoarthritis pain compared to placebo, as indicated by the Canine Brief Pain Inventory scale, a well validated and widely used scoring system.
News For PETX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
16:22 EDTPETXOn The Fly: Top stock stories for Monday
Subscribe for More Information
12:24 EDTPETXOn The Fly: Top stock stories at midday
Stocks on Wall Street were sharply lower at midday after a surprise power play by the country's Prime Minister may lead to either his exit from power or the country's exit from the euro zone. ECONOMIC EVENTS: In Europe, Greek Prime Minister Alexis Tsipras called a surprise referendum for July 5 on the terms put forth by the country’s creditors in exchange for additional rescue funding. Meanwhile, the European Central Bank decided not to expand its emergency liquidity assistance to Greek banks, leading the country to shut down its banking system and move to impose capital controls. In Asia, the People’s Bank of China cut the one-year lending rate by 25 basis points to 4.85% and lowered the amount of reserves certain banks are required to hold by 50 basis points, but the Shanghai Composite still closed the day with another 3.3% in losses. In the U.S., the National Association of Realtors' pending home sales index rose 0.9% to 112.6 in May, which was roughly in-line with expectations but also marked the highest level since April 2006. COMPANY NEWS: Shares of several coal miners advanced after the Supreme Court overturned the Environmental Protection Agency's air quality regulations for power plants, stating that the regulator did not properly take into account the costs to utilities and others in the sector. Peabody Energy (BTU) rose 5% after the ruling, while Arch Coal (ACI) gained 8% and Cloud Peak Energy (CLD) added about 3%. MAJOR MOVERS: Among the notable gainers was Aratana Therapeutics (PETX), which jumped 17.5% after the company announced results from its study of capromorelin, the company's therapeutic for appetite stimulation in dogs. Also higher was Amphenol (APH), which gained 4% after announcing it has entered into exclusive negotiations and has made a binding offer to acquire 100% of the shares of FCI Asia, which is involved in interconnect solutions for the telecom, datacom, wireless communications and industrial markets, for $1.275B from its private equity owner Bain Capital. Among the noteworthy losers were bond insurers MBIA (MBI), which dropped 18%, and Assured Guaranty (AGO), which fell 13.5%, after Puerto Rico's Governor said that the commonwealth would not be able to pay its debts and called for concessions from the island’s creditors. Both stocks were downgraded at BTIG following the news. Also lower following the news in Puerto Rico were First Bancorp (FBP), the bank holding company for FirstBank Puerto Rico, and Popular (BPOP), the parent of Banco Popular de Puerto Rico. Shares of Vitae Pharmaceuticals (VTAE) declined 16% after the company announced that an ongoing Phase 2 trial of its treatment of overweight type 2 diabetic patients did not meet partner Boehringer Ingelheim's predefined endpoint criteria. INDEXES: Near midday, the Dow was down 218.57, or 1.22%, to 17,728.11, the Nasdaq was down 69.65, or 1.37%, to 5,010.85, and the S&P 500 was down 25.68, or 1.22%, to 2,075.81.
09:18 EDTPETXOn The Fly: Pre-market Movers
Subscribe for More Information
08:22 EDTPETXAratana probability of success for AT-002 increased to 95% at William Blair
William Blair increased its probability of success for AT-002 in dogs to 95% after Aratana Therapeutics announced results for the drug after the bell on Friday. The firm also noted that the company’s third small molecule candidate, AT-003 to treat post-surgical pain in dogs, is set to report top-line results in the second half of next month. William Blair keeps an Outperform rating on Aratana shares.
07:16 EDTPETXAratana Therapeutics shares likely to rise, says Piper Jaffray
Subscribe for More Information
June 26, 2015
16:52 EDTPETXAratana Therapeutics up 41% after positive pivotal results for AT-002
Subscribe for More Information
16:41 EDTPETXAratana Therapeutics to resume trading at 4:45 pm ET
Subscribe for More Information
16:12 EDTPETXAratana Therapeutics announces positive pivotal results for AT-002
Subscribe for More Information
16:06 EDTPETXAratana Therapeutics trading halted, news pending
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use